Subject(s)
Melanoma/secondary , Skin Neoplasms/pathology , Diagnosis, Differential , Fatal Outcome , Female , Humans , Melanoma/diagnosis , Middle Aged , Neoplasm MetastasisABSTRACT
Calcipotriol is an analogue of vitamin D3 with effect on epidermal keratinization, cellular division and modulation of immune response. An evaluation of its therapeutic effect when given in twenty-five psoriatic patient with less than 25% of their body surface affected was done. The medication was applied twice daily during six weeks on involved areas. The evolution was evaluated by the psoriatic area and severity index (PASI) analysis. The evaluation of initial and terminal PASI analysis revealed a decrease in the psoriatic activity that fluctuated from 25% to 100%, with a 61% average. A reactivation in the psoriatic lesion was noticed two weeks after the medication was halted; thereafter, the calcipotriol was restarted for an additional four weeks and a decrease in their PASI with a 74% average was achieved. There were no important side effects reported. Calcipotriol is effective in the treatment of psoriasis and it is an important addition to the therapeutic medications available to treat psoriasis. It is important to give the treatment for longer periods of time for evaluating the possibility to induce prolonged remissions.
Subject(s)
Calcitriol/analogs & derivatives , Dermatologic Agents/administration & dosage , Psoriasis/drug therapy , Administration, Topical , Calcitriol/administration & dosage , Female , Humans , Male , Ointments , Time FactorsABSTRACT
The polymerase chain reaction was used to amplify DNA sequences of the etiologic agent of Lyme disease, Borrelia burgdorferi, and was applied to the detection of the spirochete in humans and dogs. Oligonucleotide primers used in the reaction flank a 244-base-pair representing part of the variable region V4 of the B. burgdorferi 16S rRNA from biopsies of patients with acrodermatitis, and in synovial fluid from a dog with arthritis. These data suggest the presence of the disease in our state.
Subject(s)
Borrelia burgdorferi Group/isolation & purification , DNA, Bacterial/analysis , Polymerase Chain Reaction , Animals , Biopsy , Borrelia burgdorferi Group/genetics , Dogs , Humans , Skin/microbiology , Synovial Fluid/microbiologyABSTRACT
We report the excellent therapeutic response of actinomycetoma treated with amikacin-trimethoprim-sulfamethoxazole. The medication was given in cycles for 5 weeks. Ninety-five percent of all cases were cured after 5, 10 or 15 weeks treatment.
Subject(s)
Actinomycetales Infections/drug therapy , Amikacin/therapeutic use , Sulfamethoxazole/therapeutic use , Trimethoprim/therapeutic use , Amikacin/administration & dosage , Animals , Streptomycin/therapeutic use , Sulfamethoxazole/administration & dosage , Tetracyclines/therapeutic use , Trimethoprim/administration & dosageABSTRACT
Three mycetoma cases with pulmonary dissemination are presented. Two of them caused by N. brasiliensis and one by N. asteroides. The dissemination in one of them was by contiguity and the two other by hematogenous way. We point out the sequence of treatments used, emphasizing the excellent therapeutic result achieved with the association of sulfamethoxazole-trimethoprim and amikacin endovenously. We propose a therapeutic trial in a greater number of severe cases of mycetoma with the last antibiotic association in order to evaluate its therapeutic efficacy.
